Synthesis and antitumor activity of cyclopentane-fused anthraquinone derivatives.

Anthracyclines Anthraquinone Antitumor activity Carbocyclization Cellular uptake DNA binding Doxorubicin Lipophilicity Lysosomes P-glycoprotein Topoisomerase 1

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
30 Dec 2023
Historique:
received: 07 11 2023
revised: 21 12 2023
accepted: 25 12 2023
medline: 5 1 2024
pubmed: 5 1 2024
entrez: 4 1 2024
Statut: aheadofprint

Résumé

In our pursuit of developing novel analogs of anthracyclines with enhanced antitumor efficacy and safety, we have designed a synthesis scheme for 4,11-dihydroxy-5,10-dioxocyclopenta[b]anthracene-2-carboxamides. These newly synthesized compounds exhibit remarkable antiproliferative potency against various mammalian tumor cell lines, including those expressing activated mechanisms of multidrug resistance. The structure of the diamine moiety in the carboxamide side chain emerges as a critical determinant for anticancer activity and interaction with key targets such as DNA, topoisomerase 1, and ROS induction. Notably, the introduced modification to the doxorubicin structure results in significantly increased lipophilicity, cellular uptake, and preferential distribution in lysosomes. Consequently, while maintaining an impact on anthracyclines targets, these novel derivatives also demonstrate the potential to induce cytotoxicity through pathways associated with lysosomes. In summary, derivatives of cyclic diamines, particularly 3-aminopyrrolidine, can be considered a superior choice compared to aminosugars for incorporation into natural and semi-synthetic anthracyclines or new anthraquinone derivatives, aiming to circumvent efflux-mediated drug resistance.

Identifiants

pubmed: 38176358
pii: S0223-5234(23)01070-X
doi: 10.1016/j.ejmech.2023.116103
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116103

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Alexander S Tikhomirov (AS)

Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow, 119021, Russian Federation.

Yuri B Sinkevich (YB)

Mendeleyev University of Chemical Technology, 9 Miusskaya Square, Moscow, 125047, Russian Federation.

Lyubov G Dezhenkova (LG)

Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow, 119021, Russian Federation.

Dmitry N Kaluzhny (DN)

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 32 Vavilov Street, 119991, Moscow, Russian Federation.

Nikolay S Ilyinsky (NS)

Research Center for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology, Institutskiy Pereulok, 9, Dolgoprudny, 141700, Russian Federation.

Valentin I Borshchevskiy (VI)

Research Center for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology, Institutskiy Pereulok, 9, Dolgoprudny, 141700, Russian Federation.

Dominique Schols (D)

Rega Institute for Medical Research, K.U. Leuven, 3000, Leuven, Belgium.

Andrey E Shchekotikhin (AE)

Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, Moscow, 119021, Russian Federation. Electronic address: shchekotikhin@mail.ru.

Classifications MeSH